Lantheus Holdings, Inc. $LNTH Stake Increased by Principal Financial Group Inc.

Principal Financial Group Inc. boosted its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 5.5% during the 3rd quarter, HoldingsChannel reports. The fund owned 206,472 shares of the medical equipment provider’s stock after buying an additional 10,722 shares during the period. Principal Financial Group Inc.’s holdings in Lantheus were worth $10,590,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in the stock. Elevation Point Wealth Partners LLC bought a new stake in shares of Lantheus in the 2nd quarter worth about $26,000. First Horizon Corp bought a new stake in Lantheus in the third quarter valued at about $26,000. Osterweis Capital Management Inc. acquired a new stake in Lantheus during the second quarter valued at approximately $36,000. Pilgrim Partners Asia Pte Ltd bought a new position in Lantheus during the 3rd quarter worth approximately $59,000. Finally, Tripletail Wealth Management LLC bought a new position in Lantheus during the 3rd quarter worth approximately $68,000. 99.06% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

LNTH has been the subject of a number of research analyst reports. Mizuho boosted their price target on Lantheus from $60.00 to $72.00 and gave the company an “outperform” rating in a report on Wednesday, December 17th. Truist Financial boosted their target price on shares of Lantheus from $80.00 to $82.00 and gave the company a “buy” rating in a research note on Thursday, December 18th. Finally, Weiss Ratings upgraded shares of Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, January 6th. Five investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, Lantheus presently has a consensus rating of “Moderate Buy” and a consensus target price of $78.00.

Lantheus Price Performance

Shares of NASDAQ LNTH opened at $67.28 on Thursday. Lantheus Holdings, Inc. has a 1-year low of $47.25 and a 1-year high of $111.29. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.67 and a quick ratio of 2.49. The business’s fifty day moving average price is $66.04 and its two-hundred day moving average price is $59.52. The firm has a market capitalization of $4.46 billion, a PE ratio of 28.27 and a beta of -0.08.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.